Melanoma, the great leap forward
Metastatic melanoma has been among the most difficult cancers to treat with limited and highly toxic treatment options. Recent advances in immune checkpoint inhibitors and molecularly targeted drugs have profoundly changed the life expectancy and quality of life of patients with metastatic melanoma. Therapeutic options are broadening for these patients and these recent articles in the BJC illustrate the trajectory of current research.
Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis Open
B Weide, M Elsässer, P Büttner, A Pflugfelder, U Leiter, T K Eigentler, J Bauer, M Witte, F Meier and C Garbe
British Journal of Cancer 107: 422-428; Published online, 10 July 2012; doi:10.1038/bjc.2012.306
Sorafenib in advanced melanoma: a critical role for pharmacokinetics? Open
N Pécuchet, C Lebbe, O Mir, B Billemont, B Blanchet, N Franck, M Viguier, R Coriat, M Tod, M-F Avril and F Goldwasser
British Journal of Cancer 107: 455-461; Published online, 05 July 2012; doi:10.1038/bjc.2012.287
Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours Open
M Millward, C Underhill, S Lobb, J McBurnie, S J Meech, J Gomez-Navarro, M A Marshall, B Huang and C B Mather
British Journal of Cancer 108: 1998-2004; Published online, 07 May 2013; doi:10.1038/bjc.2013.227
Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma Open
B Sherrill, J Wang, S Kotapati and K Chin
British Journal of Cancer 109: 8-13; Published online, 20 June 2013; doi:10.1038/bjc.2013.298
KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases Open
A Zebary, M Jangard, K Omholt, B Ragnarsson-Olding and J Hansson
British Journal of Cancer 109: 559-564; Published online, 16 July 2013; doi:10.1038/bjc.2013.373
Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma Open
R Plummer, P Lorigan, E Brown, R Zaucha, V Moiseyenko, L Demidov, V Soriano, E Chmielowska, R Andrés, G Kudryavtseva, C Kahatt, S Szyldergemajn, S Extremera, B de Miguel, M Cullell-Young and H Calvert
British Journal of Cancer 109: 1451-1459; Published online, 29 August 2013; doi:10.1038/bjc.2013.477
Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy Open
V Chiarion-Sileni, J Pigozzo, P A Ascierto, E Simeone, M Maio, L Calabrò, P Marchetti, F De Galitiis, A Testori, P F Ferrucci, P Queirolo, F Spagnolo, P Quaglino, F Carnevale Schianca, M Mandalà, L Di Guardo and M Del Vecchio
British Journal of Cancer 110: 1721-1726; Published online, 11 March 2014; doi:10.1038/bjc.2014.126
Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients Open
C Posch, F Weihsengruber, K Bartsch, V Feichtenschlager, M Sanlorenzo, I Vujic, B Monshi, S Ortiz-Urda and K Rappersberger
British Journal of Cancer 110: 1427-1432; Published online, 11 February 2014; doi:10.1038/bjc.2014.62
The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas Open
F Seguin, M A Carvalho, D C Bastos, M Agostini, K G Zecchin, M P Alvarez-Flores, A M Chudzinski-Tavassi, R D Coletta and E Graner
British Journal of Cancer 107: 977-987; Published online, 14 August 2012; doi:10.1038/bjc.2012.355
BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma Open
J S Wilmott, A M Menzies, L E Haydu, D Capper, M Preusser, Y E Zhang, J F Thompson, R F Kefford, A von Deimling, R A Scolyer and G V Long
British Journal of Cancer 108: 924-931; Published online, 12 February 2013; doi:10.1038/bjc.2013.29
Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice Open
L Heinzerling, S Kühnapfel, D Meckbach, M Baiter, E Kaempgen, P Keikavoussi, G Schuler, A Agaimy, J Bauer, A Hartmann, F Kiesewetter and R Schneider-Stock
British Journal of Cancer 108: 2164-2171; Published online, 11 April 2013; doi:10.1038/bjc.2013.143
Inducing apoptosis of cancer cells using small-molecule plant compounds that bind to GRP78 Open
S Martin, H K Lamb, C Brady, B Lefkove, M Y Bonner, P Thompson, P E Lovat, J L Arbiser, A R Hawkins and C P F Redfern
British Journal of Cancer 109: 433-443; Published online, 27 June 2013; doi:10.1038/bjc.2013.325
partner of